DLBCL/HGBL-MYC/BCL2 was defined as a distinct entity by the fifth edition of the WHO classification of hematolymphoid tumors in 2023 and is associated with advanced disease and extranodal involvement of the bone marrow and central nervous system (CNS).1 This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.